Showing 5431-5440 of 10417 results for "".
- Study: Bimekizumab Not Linked to Higher Depression Risk vs. IL-23 Inhibitorshttps://practicaldermatology.com/news/study-bimekizumab-not-linked-to-higher-depression-risk-vs-il-23-inhibitors/2485849/Bimekizumab was not associated with increased risk of depression or suicidal ideation compared with IL-23 inhibitors, a new study from George Washington University indicated. "Bimekizumab, a dual IL-17A/F inhibitor, has demons
- Analysis: Tapinarof Cream Yields Improved Sleep in Pediatric ADhttps://practicaldermatology.com/news/analysis-links-tapinarof-cream-to-early-sleep-improvements-in-pediatric-ad/2485802/A new analysis of the phase 3 ADORING 1 and ADORING 2 trials showed that tapinarof cream, 1% (VTAMA, Organon) was associated with early and sustained improvements in sleep-related patient-reported outcomes in pediatric patients with moderate to severe atopic derma
- Most Nations Off Track to Meet 2030 Skin NTD SDG Targets: Reporthttps://practicaldermatology.com/news/most-nations-off-track-to-meet-2030-skin-ntd-sdg-targets-report/2485823/A new report in JAMA Dermatology revealed that most countries are unlikely to achieve the World Health Organization (WHO) target of a 75% reduction in disability-adjusted life-years (DALYs) from skin-related neglected tropical diseases (NTDs) from 2020 lev
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://practicaldermatology.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin
- Remibrutinib Data at AAAAI Suggests Potential Expansion Beyond CSUhttps://practicaldermatology.com/news/remibrutinib-data-at-aaaai-highlight-expanded-potential-beyond-csu/2485784/New data on the selective Bruton’s tyrosine kinase inhibitor remibrutinib (Rhapsido) is slated for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, to be held February 27 to March 2 in Philadelphia.
- LIBERTY-CSU CUPID-C: Improved Itch in Spontaneous Chronic Urticaria with Dupliumabhttps://practicaldermatology.com/news/liberty-csu-cupid-c-improved-itch-in-spontaneous-chronic-urticaria-with-dupliumab/2485781/Dupilumab significantly reduced itch and hives severity in patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite histamine 1–receptor antagonist (H1-AH) therapy, according to results from the phase 3 LIBERTY-CSU CUPID-C trial published
- Economic Analysis Shows Wide Range in Annual Sunscreen Expenseshttps://practicaldermatology.com/news/economic-analysis-shows-wide-range-in-annual-sunscreen-expenses/2485778/A new 2025 economic evaluation of annual sunscreen costs found wide variation depending on unit pricing and clothing coverage. Investigators conducted the analysis from July through August 2025, modeling the cost of sunscreen
- Report: Skin Lightening Resurgence Raises Safety Concernshttps://practicaldermatology.com/news/report-skin-lightening-resurgence-raises-safety-concerns/2485703/A growing global resurgence in skin lightening (SL) practices is raising renewed safety and public health concerns, according to a recent publication in the Journal of the American Academy of Dermatology.
- AI Footprint Grows in Aesthetic Surgery: Analysishttps://practicaldermatology.com/news/ai-footprint-grows-in-aesthetic-surgery-specialty-analysis/2485685/Artificial intelligence (AI) is increasingly embedded in plastic surgery, according to a narrative review published in Aesthetic Surgery Journal. Authors used PubMed searches of arti
- Study Details Creation of First Patient Decision Aid for Adult ADhttps://practicaldermatology.com/news/study-details-creation-of-first-patient-decision-aid-for-adult-ad/2485671/A new paper details the development of a patient decision aid (PDA) designed to support shared decision-making for adults with moderate to severe atopic dermatitis (AD), unique in this instance for targeting previously addressed systemic treatment selection for ad